Perspective Complete Prescribing Facts OPDIVO® (nivolumab) is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) which has relapsed or progressed following autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or soon after three or more lines of systemic therapy that includes autologous